Background and aims: According to clinical trials, the treatment of patients with chronic hepatitis C CHC with second-generation direct acting antiviral agents DAAs is highly efficient and well tolerated. The goal of this study was to investigate the effectiveness and safety of various combinations of these drugs during their first 2 years of use in the real-world practice of French general hospitals. Methods: Data from patients treated with all-oral DAAs in 24 French non-academic hospital centers from March 1, to January 1, , were prospectively recorded.
The sustained virological response weeks after treatment SVR was estimated and severe adverse events SAE were evaluated and their predictive factors were determined using logistic regression.
Results: Data from patients were analyzed. The SVR was Sofosbuvir-ribavirin was less effective than other regimens. Sixty-four severe adverse events SAE were observed in 59 [5. Serum creatinine increased during treatment mean 8. Patient-reported overall tolerance was excellent, and patient-reported fatigue decreased during and after treatment. Conclusions: Second generation DAAs combinations are as effective and well tolerated in a Β« real-world Β» population as in clinical trials.
Further studies are needed on renal tolerance. Abstract Background and aims: According to clinical trials, the treatment of patients with chronic hepatitis C CHC with second-generation direct acting antiviral agents DAAs is highly efficient and well tolerated.
Publication types Multicenter Study Observational Study. Substances Antiviral Agents.
